Villepinte (France), February 11, 2020 – Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional imaging, will attend ECR (European Congress of Radiology) 2020, from March 11th to 15th in Vienna (Austria). This year, healthcare professionals will be able to experience the Group's latest innovations, its patient pathway and its comprehensive educational program, at the Tech Gate Building near the Austria Center Vienna.
Women’s Health and Augmented Intelligence in focus
This immersion will begin with the discovery of two new areas dedicated to Augmented Intelligence and Women's Health.
On this occasion, Guerbet reaffirms its ambition to extend its portfolio of digital AI solutions with the launch of icobrain®. Demos will be performed on this Saas (Software as a Service) artificial intelligence-based medical imaging solution, designed to help radiologists and neurologists diagnose and monitor patients with neurological disorders.
The Women’s Health space will be the opportunity to learn more about the use of Lipiodol® Ultra Fluid for Hysterosalpingography within infertility management and Patent Blue V for sentinel node identification before biopsy in patients with operable breast cancer.
A Patient Pathway to practice on Guerbet’s solutions
In addition to this focus, Guerbet will exhibit its current range of contrast media, injections systems, medical devices and digital solutions for CT, MR, Cath Lab and interventional radiology. Throughout a patient pathway, visitors will interact with many demonstrations to discover our solutions.
A comprehensive educational program with 16 courses and 2 symposia
From Wednesday to Friday, Guerbet will be launching a new and unique program called “On the Pathway to Knowledge”. This shall give the opportunity to radiologists, residents, radiographers, scientists involved in routine or research medical imaging the chance to improve their knowledge in various areas of interest, such as Artificial Intelligence, emerging radiological techniques, safety and innovation in contrast agents. The audience will meet international experts, key opinion leaders and pioneers in different fields.
The two Guerbet symposia will focus on:
“Challenges and pitfalls of current clinical practice: where will Augmented Intelligence bring value?”
- Thursday, March 12 at 12:45pm
- Auditorium at Tech Gate
“Challenge Your Expertise in GI (gastro-intestinal) Advanced Clinical Cases”
- Friday, March 13 at 12:45pm
- Auditorium at Tech Gate
Two communications about gadopiclenol
The results from two clinical studies on gadopiclenol, Guerbet’s new macrocyclic gadolinium-based contrast agent in development, will be presented during the ECR scientific sessions:
“Impact of the novel contrast agent gadopiclenol on decision making in patients with brain metastases”
- Oral presentation in session “Gadolinium retention and neurovascular imaging”
- Wednesday, March 11 at 2pm
“Pharmacokinetics and safety of gadopiclenol in healthy volunteers and in patients with impaired renal function”
- ePoster in The Voice of EPOS session
- Thursday, March 12 at 9am
Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.